CD&R taps Wall Street for $3.1B debt on Option Care acquisition despite 65% PE deal collapse

Clayton, Dubilier & Rice secured $3.1 billion in committed debt financing from a Wall Street banking syndicate for its joint acquisition with McKesson Corp. of Option Care Health. The financing closed in the same week global private equity transaction value fell 65% year-over-year, making the commitment a signal that healthcare infrastructure deals still command institutional support when others do not.

McKesson, the $73 billion pharmaceutical distributor, is partnering with CD&R to take Option Care private in a transaction that values the home infusion therapy provider at approximately $5.1 billion including assumed debt. The $3.1 billion debt package represents roughly 61% leverage on enterprise value, a structure that would have been unremarkable in 2021 but now marks one of the larger buyout financings closed in the second half of 2024. The banking group includes JPMorgan, Bank of America, and Goldman Sachs, though specific commitment sizes remain undisclosed. Pricing guidance has not been published, but comparable healthcare services LBOs in the past six months have cleared at SOFR plus 425 to 475 basis points for senior secured tranches.

The transaction solves two problems simultaneously. McKesson gains operational control of a $4.2 billion revenue business that distributes specialty pharmaceuticals directly to patients' homes, a margin-accretive adjacency to its core hospital and retail distribution networks. CD&R acquires a scaled platform in a subsector where reimbursement visibility is improving and where private equity has struggled to build from scratch. Home infusion grew 12% annually from 2020 to 2023 as payers shifted complex therapies out of hospital settings, and Option Care holds roughly 23% market share in a fragmented field. The debt commitment suggests lenders believe that revenue stream can withstand a refinancing cycle in 2027 or 2028 without material valuation compression.

What makes this financing notable is its isolation. PE deal volume in October fell to $48 billion globally, the lowest monthly figure since March 2020, and the number of transactions valued above $1 billion dropped to 11 from 29 in the prior-year period. CD&R's ability to close $3.1 billion in debt during that window indicates that lenders are still underwriting buyouts selectively, particularly in healthcare services where earnings are tied to demographic tailwinds rather than discretionary spending. The firm's prior healthcare bets — including a $5.2 billion exit from Sedgwick in 2023 and ongoing holds in athenahealth and Belron — have returned capital on schedule, which matters when credit committees evaluate sponsor track records.

Allocators should monitor whether this financing clears the syndication process without meaningful flex. If the banks hold less than 15% of the $3.1 billion debt on their balance sheets by year-end, it confirms that institutional loan buyers are still active in healthcare at scale. A slower syndication — where banks retain 30% or more into Q1 2025 — would signal that even high-quality healthcare LBOs face distribution challenges in the current rate environment. The McKesson partnership also creates a template for future corporate-sponsor co-buys, a structure that has accounted for 18% of U.S. buyouts above $2 billion since 2022 but remains underutilized relative to the 2006-2007 cycle.

CD&R has now deployed roughly $11 billion across six platform acquisitions since January 2023, making it one of the few mega-funds maintaining deal pace without relying on continuation vehicles or preferred equity. The Option Care financing will close in Q4 2024, subject to regulatory clearance that is expected without material concessions given McKesson's existing relationships with the Federal Trade Commission.